BioGend Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
BioGend Therapeutics has a total shareholder equity of NT$956.8M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.1B and NT$93.7M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
Interest coverage ratio | n/a |
Cash | NT$724.27m |
Equity | NT$956.77m |
Total liabilities | NT$93.71m |
Total assets | NT$1.05b |
Financial Position Analysis
Short Term Liabilities: 6733's short term assets (NT$801.2M) exceed its short term liabilities (NT$46.3M).
Long Term Liabilities: 6733's short term assets (NT$801.2M) exceed its long term liabilities (NT$47.5M).
Debt to Equity History and Analysis
Debt Level: 6733 is debt free.
Reducing Debt: 6733 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6733 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6733 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.3% each year